Longitudinal serological study of SARS-CoV-2 positive individuals

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00028057

Enrollment

200

Registered

2022-02-08

Start date

2020-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Patients suffering from COVID-19. In the study, blood samples from patients infected with SARS-CoV-2 are examined. Various serological tests are carried out. These include enzyme-linked immun

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: In addition to the signed declaration of consent, the prerequisite for participation is the clinical suspicion of an infection with SARS-CoV-2.

Exclusion criteria

Exclusion criteria: Exclusion criteria are: Primary immunodeficiency, severe liver or kidney disease, test persons taking immunomodulating medication, pregnant women and persons suffering from an oncological disease.

Design outcomes

Primary

Measure	Time frame
Hypothesis: The severity of the disease after infection with SARS-CoV-2 influences the number and quality of detectable antibodies against SARS-CoV-2.	—

Secondary

Measure	Time frame
The immune system of sick people reacts individually to SARS-CoV-2 with regard to the humoral immune response.	—

Countries

Germany

Contacts

Public ContactPaul Lange

Institut für Molekulare Diagnostik und Bioanalytik gGmbH

pauljorislange@mailbox.orgDE +49

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026